Results 61 to 70 of about 447,577 (315)
Molecular Oncology, EarlyView.Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau +36 more
wiley +1 more source
Regulation of Fibrotic Processes in the Liver by ADAM Proteases
Cells, 2019 Fibrosis in the liver is mainly associated with the activation of hepatic stellate cells (HSCs). Both activation and clearance of HSCs can be mediated by ligand−receptor interactions.
Dirk Schmidt-Arras, Stefan Rose-John
doaj +1 more source
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor [PDF]
Oncogene, 2010 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the gatekeeper residue.
D, Ercan +12 more
openaire +2 more sources
E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer
Molecular Oncology, EarlyView.Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov +3 more
wiley +1 more source
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors [PDF]
Journal of Thoracic Oncology, 2013 Non-small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case of the most common EGFR mutations affecting exon 18 (G719X), 19 (inframe deletions), and 21 (L858R and L861Q). However, the frequency of compound (i.e., double or complex)
Kobayashi, Susumu +7 more
openaire +2 more sources
, 2023 In high grade astrocytoma, which are particularly aggressive and difficult to treat, interaction between integrin β1 (ITGB1) and the epidermal growth factor receptor (EGFR) causes therapy resistance owed to enhanced activation of the PI3K/Akt survival ...
Khoudari, Hamza
core
, 2023 Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype due to its lack of targeted therapies and poor prognosis. In order to treat patients with these tumors, efforts have been made to explore feasible targets.
Aiguo Wu (315321) +19 more
core +1 more source
EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives [PDF]
, 2022 EGFR mutations are the first identified targetable driver alterations in advanced non-small cell lung cancer (NSCLC), for which specific epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been developed.
Antonio Rossi, Ettore Mari
core +1 more source
Molecular Oncology, EarlyView.Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau +8 more
wiley +1 more source
Indian Journal of Endocrinology and Metabolism, 2021 Objectives: This meta-analysis of randomized clinical trials (RCT) intends to evaluate the efficacy of DPP4 Inhibitors (DPP4I) compared with placebo, other antidiabetics (or DPP4I) on renal outcomes, adverse events (AEs), and all-cause mortality. Methods:
Saikat K Dalui +5 more
doaj +1 more source